 Shares of Imago BioSciences Inc. IMGO, -3.87 soared toward an eight-month high in premarket trading Monday, after the biopharmaceutical company developing treatments for myeloproliferative neoplasms MPNs and other bone marrow diseases announced an agreement to be acquired by Merck Co. Inc. MRK, 1.88 in a cash deal with a equity value of 1.35 billion. Under terms of the deal, Merck will pay 36.00 for each Imago share, which represents a 106.9 premium to Fridays closing price of 17.40. 